The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma

被引:2
作者
Prestwich, Robin J. [2 ]
Scott, Karen J. [2 ]
Brown, Joanne [2 ]
Harnden, Patricia [1 ]
Whelan, Peter [3 ]
Cartledge, Jon [3 ]
O'Donnell, Dearbhaile [5 ]
Pandha, Hardev S. [4 ]
Selby, Peter J. [2 ]
Banks, Rosamund E. [2 ]
Merrick, Alison E. [2 ]
Melcher, Alan A. [1 ,2 ]
机构
[1] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Dept Pathol, Leeds LS9 7TF, W Yorkshire, England
[2] Univ Leeds, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[3] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Dept Urol, Leeds LS9 7TF, W Yorkshire, England
[4] Univ Surrey, Postgrad Med Sch, Guildford, Surrey, England
[5] St James Univ Hosp, Acad Unit Med & Clin Oncol, Dublin, Ireland
关键词
renal cell carcinoma; autologous; vaccine; adjuvant; DENDRITIC CELLS; ANTITUMOR VACCINATION; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; T-LYMPHOCYTES; PHASE-III; EXPRESSION; CANCER; IMMUNOTHERAPY; INDUCE;
D O I
10.1111/j.1464-410X.2008.08113.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To report the results of a programme aimed at determining the feasibility of autologous renal cell carcinoma (RCC) tissue collection and vaccine preparation within the setting of a UK National Health Service Cancer Centre. Patients undergoing nephrectomy for suspected renal tumours were identified from theatre lists between April 2005 and July 2007. Samples of tumour were freshly cut from nephrectomy specimens. If tissue collection failed the reason was recorded prospectively. Cell viability was assessed after sample sieving. Freeze-thaw lysates were prepared from viable tumour cells, and the immunogenicity tested by pulsing onto dendritic cells (DC). Of 84 patients, 83 had a histological diagnosis of RCC; samples were obtained from 29 of these 83 (35%). Reasons for failure in tissue collection included that the tumour was too small or haemorrhagic/necrotic, pre-surgical embolization, and difficulties with fresh tumour collection out of normal working hours. Viable tumour cells were obtained in 12 of the 29 samples (41%); no factor was able to predict the production of viable cells. Unmodified lysates did not activate DC. An autologous RCC vaccination programme might fail to generate vaccines for a substantial proportion of eligible patients in the setting of a clinical cancer centre.
引用
收藏
页码:740 / 746
页数:7
相关论文
共 31 条
[1]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[2]   Therapeutic dendritic cell vaccination of patients with renal cell carcinoma [J].
Berntsen, A ;
Geertsen, PF ;
Svane, IM .
EUROPEAN UROLOGY, 2006, 50 (01) :34-43
[3]  
Booth C, 1997, LAB INVEST, V76, P843
[4]   Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial [J].
Clark, JI ;
Atkins, MB ;
Urba, WJ ;
Creech, S ;
Figlin, RA ;
Dutcher, JP ;
Flaherty, L ;
Sosman, JA ;
Logan, TF ;
White, R ;
Weiss, GR ;
Redman, BG ;
Tretter, CPG ;
McDermott, D ;
Smith, JW ;
Gordon, MS ;
Margolin, KA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3133-3140
[5]   Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma [J].
Coppin, C .
CANCER TREATMENT REVIEWS, 2004, 30 (06) :589-593
[6]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[7]  
Galligioni E, 1996, CANCER, V77, P2560, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO
[8]  
2-P
[9]   Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma [J].
Gastl, G ;
Ebert, T ;
Finstad, CL ;
Sheinfeld, J ;
Gomahr, A ;
Aulitzky, W ;
Bander, NH .
JOURNAL OF UROLOGY, 1996, 155 (01) :361-367
[10]   Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? [J].
Guida, M. ;
Colucci, G. .
ANNALS OF ONCOLOGY, 2007, 18 :149-152